John Frenz Becomes CASSS President
Tuesday, March 22, 2016
Posted by: Jeanne Marie Tokunaga
John Frenz, Vice President of Manufacturing with Alnylam Pharmaceuticals, has been elected President of the CASSS Board of Directors.
During his presidency, Frenz hopes to help CASSS further its mission of bringing together professionals from the various facets of biopharmaceutical development.
“I want to continue the evolution of CASSS as an innovative, effective non-profit that brings academics, regulators and industry professionals together to resolve scientific challenges,” Frenz said. “I’d also like to continue to explore how our mission can be enlarged to help address the many large, unmet needs in global health challenges.”
Frenz becomes President after more than 20 years as a volunteer leader with CASSS. He notes that volunteering with the organization has been both personally and professionally rewarding.
“It has been a great way to network with a very diverse assortment of industry colleagues and a great way to give back to the biotech community and, ultimately, to help patients. Helping others is what all the volunteers with CASSS most care about.”
Prior to joining Alnylam in 2013, Frenz was Vice President of Operations at GlobeImmune, Inc., where he oversaw clinical supply of seven products across two Phase II and multiple Phase I trials. Frenz received his B.S. in Chemical Engineering from Yale University, an M.S. in Chemical Engineering from the Massachusetts Institute of Technology, and his Ph.D. in Chemical Engineering from Yale.
In other changes to CASSS volunteer leadership, Wassim Nashabeh was elected Vice President, and Brian Nunnally and Anthony Lubiniecki joined the board.
Nashabeh is the Global Head, Policy and International Operations, Pharma Technical Regulatory with Roche. Nunnally is the Director of Global Stability at Biogen, and Lubiniecki is a biotechnologist with Janssen Pharmaceuticals of Johnson & Johnson.
To see CASSS' entire Board of Directors, click here.